Literature DB >> 15519505

Best practice in assessing ototoxicity in children with cancer.

Roderick Skinner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15519505     DOI： 10.1016/j.ejca.2004.08.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  13 in total

1.  Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Authors:  Giuliano Ciarimboli; Dirk Deuster; Arne Knief; Michael Sperling; Michael Holtkamp; Bayram Edemir; Hermann Pavenstädt; Claudia Lanvers-Kaminsky; Antoinette am Zehnhoff-Dinnesen; Alfred H Schinkel; Hermann Koepsell; Heribert Jürgens; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

2.  Cisplatin ototoxicity in rat cochlear organotypic cultures.

Authors:  Dalian Ding; Jingchun He; Brian L Allman; Dongzhen Yu; Haiyan Jiang; Gail M Seigel; Richard J Salvi
Journal:  Hear Res       Date:  2011-08-12       Impact factor: 3.208

3.  Co-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice.

Authors:  Yongqi Li; Dalian Ding; Haiyan Jiang; Yong Fu; Richard Salvi
Journal:  Neurotox Res       Date:  2011-04-01       Impact factor: 3.911

4.  Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation.

Authors:  Patricia Helena Pecora Liberman; Christiane Schultz; María Valéria Schmidt Goffi-Gómez; Célia B G Antoneli; Martha Motoro Chojniak; Paulo Eduardo Novaes
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

5.  Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

Authors:  Jorrit W van As; Henk van den Berg; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-05-07

6.  Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.

Authors:  Anna Rita Fetoni; Francesca Brigato; Eugenio De Corso; Daniela Lucidi; Bruno Sergi; Emanuele Scarano; Jacopo Galli; Antonio Ruggiero
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-13       Impact factor: 3.236

7.  Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

Authors:  Jorrit W van As; Henk van den Berg; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2020-01-21

8.  Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood.

Authors:  P H P Liberman; M V S Goffi-Gomez; C Schultz; P L Jacob; C A A de Paula; E L Sartorato; G T Torrezan; E N Ferreira; D M Carraro
Journal:  Clin Transl Oncol       Date:  2018-10-25       Impact factor: 3.405

Review 9.  Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

Authors:  Jorrit W van As; Henk van den Berg; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2018-07-05

10.  Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients.

Authors:  Alexandra Nitz; Evangelos Kontopantelis; Stefan Bielack; Ewa Koscielniak; Thomas Klingebiel; Thorsten Langer; Marios Paulides
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.